Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis

Archives of Neurology

Volumn 66, Issue 5, 2009, Pages 659-661

  Strober, Jonathan ^a   Cowan, Morton J ^a   Horn, Biljana N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BUSULFAN; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; METHOTREXATE; MORPHINE SULFATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRIDOSTIGMINE; RITUXIMAB; VANCOMYCIN;

ADOLESCENT; AFRICAN AMERICAN; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY BLOOD LEVEL; ARTICLE; BACTEREMIA; CASE REPORT; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKOCYTE COUNT; LIMB WEAKNESS; MALE; MOOD DISORDER; MUCOSA INFLAMMATION; MYASTHENIA GRAVIS; NEUTROPHIL COUNT; OPHTHALMOPLEGIA; OROPHARYNX; PATHOGENESIS; PERIPHERAL BLOOD STEM CELL; PLASMAPHERESIS; PRIORITY JOURNAL; PTOSIS; SKELETAL MUSCLE; STAPHYLOCOCCUS EPIDERMIDIS; SUICIDAL BEHAVIOR; THERAPY EFFECT; THYMECTOMY; TREATMENT RESPONSE; WALKING DIFFICULTY;

ADOLESCENT; AUTOANTIBODIES; CHOLINESTERASE INHIBITORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; OPHTHALMOPLEGIA; PLASMAPHERESIS; PYRIDOSTIGMINE BROMIDE; RECEPTORS, CHOLINERGIC; SYNAPTIC TRANSMISSION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 66249112799     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.28     Document Type: Article

References (10)

1. Tüzün E, Li J, Saini S, Yang H, Premkumar C. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol. 2007;182(1-2):167-176. (Pubitemid 46026716)
2. Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin Immunol. 2000;94(2):75-77. (Pubitemid 30067872)
3. Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci. 2008;1132:305-314.
4. Lin PT, Martin B, Weinacker A, So Y. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve. 2006;33(3):433-435. (Pubitemid 43305922)
5. Gladstone DE, Brannagan TH, Schwartzman RJ, Prestrud AA, Brodsky I. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry. 2004;75(5):789-791. (Pubitemid 38526702)
6. Nelson JL, Torrez R, Min Louie F, Choe OS, Strob R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl. 1997;48:23-29. (Pubitemid 27223595)
7. Zaja F, Barillari G, Russo D, Silvestri F, Fanin R, Baccarani M. Myastenia gravis after allogeneic bone marrow transplantation: a case report and a review of the literature. Acta Neurol Scand. 1997;96(4):256-259. (Pubitemid 27402495)
8. Ozyurek E, Cowan MJ, Koerper MA, Baxter-Lowe L-A, Dvorak CC, Horn BN. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant. 2008;42(2):83-91.
9. Satwani P, Cooper N, Rao K, Veys P, Amrolia P. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant. 2008;41(2):173-182.
10. Marmont AM. Allogeneic haematopoietic stem cell transplantation for severe autoimmune diseases: great expectations but controversial evidence. Bone Marrow Transplant. 2006;38(1):1-4. (Pubitemid 43923081)